Instem PLC (AIM:INS) posted a loss in its latest half-year and cautioned the trading outlook for the rest of the year had also softened.
The biotech services group, which recently agreed to a £203 million takeover from Ichor Management, said revenue growth had been affected in consulting as well as SEND and Target Safety Assessment outsourced services segments of the business.
“With the added impact of inflationary pressures, adjusted EBITDA for the current year is now expected to be no greater than £11.1m,” chief executive Phil Reason added.
Half-year revenue to end June 2023 rose by 10% to £29.7 million, but Instem slipped to an interim loss of £70,000 from a profit of £2 million this time a year ago.